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ABSTRACT 
Rev MlO is a ^ans-dominant negative inhibitor of HIV replication. Hence, stable transduction of CD4"'" T 
cells with Rev M l O represents a novel gene therapy aimed at inhibiting H I V replication within these cells, 
thereby slowing the progression of AIDS. However, the immune system m a y recognize Rev M l O as foreign 
and target transduced cells for elimination. In the current study, mice were genetically immunized with a 
plasmid encoding Rev M l O , to (1) identify immune parameters that m a y be induced by Rev M l O gene trans-
fer, (2) determine the impact of repeated introduction of the Rev MlO-encoding plasmid on the immune re-
sponse to the transgene product, and (3) determine if cotransfection with a plasmid encoding TGF/31 would 
suppress the response. Kinetic studies revealed that Rev-specific IL-2-producing helper T lymphocytes (HTLs) 
appeared following the second genetic immunization, peaked after the third, and persisted at peak levels for 
at least 6 weeks. Rev-specific H T L s were CD4"'", and the development of these cells was ablated by cotrans-
fection with TGF/31. Other cytokines were not readily detectable when immune splenocytes were restimulated 
with Rev in vitro, and Rev-specific IgG antibodies were not present in the sera of these mice. To our knowl-
edge, this represents the first report that genetic immunization with Rev M l O induces an immune response 
that is dominated by IL-2-producing HTLs. Further, this study demonstrates the potential utility of intro-
ducing immunosuppressive genes as a means to control the immune response to foreign transgene products. 
O V E R V I E W S U M M A R Y encoding the mutated HIV protein Rev MlO. Further, we 
assessed the ability to Inhibit the transgene-induced H T L 
The immune system poses a major obstacle to the long-term response by cotransfer of a plasmid encoding the immuno-
success of in vivo gene therapies. Immune responses to for- suppressive cytokine TGF/31. 
eign transgene products and/or the vectors that facilitate 
gene transfer may neutralize the transgene product, elimi-
nate transfected cells, and culminate in inflammation within I N T R O D U C T I O N 
transfected tissues. The majority of studies that address 
these issues have focused on cytotoxic T lymphocyte (CTL) ''t ihe transfer of antiviral genes represents a novel strat-
and antibody responses induced by gene transfer. However, X egy aimed at inhibiting human immunodeficiency virus 
the IL-2-producing helper T lymphocyte (HTL) represents (HIV) replication and the subsequent decay of the immune sys-
a critical regulatory cell that likely influences the inductive tem in HIV-infected individuals. The nuclear protein Rev serves 
phase of the immune response following gene transfer. The as a likely target for this gene transfer-based modality, in that 
current study employed limiting dilution analysis (LDA) Rev is essential for viral replication. Rev acts in concert with 
techniques to characterize the development of IL-2-pro- host cell factors to facilitate the export of unspliced viral 
ducing HTLs induced hy genetic vaccination with a plasmid m R N A s into the cytoplasm, and is thought to be important in 
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regulating virus latency (CuUen etal, 1988; Malim etal, 1991; 
Liu et al, 1994). Introduction of two point mutations in a highly 
conserved region of Rev gives rise to a defective protein. Rev 
MlO, which acts as a fran^-dominant negative inhibitor of wild-
type Rev (Sodroski e/a/., 1986; Malim era/., 1989,1992; Bevec 
et al, 1992; Bahner et al, 1993). Importantiy, transfection of 
human T cells with Rev MlO inhibits viral replication follow-
ing challenge with HIV in vitro (Malim et al, 1992; Bevec et 
al, 1992; Woffendin et al, 1994). 
The immune system has an exquisite ability to discriminate 
self from non-self and mount a variety of effector mechanisms 
aimed at eliminating non-self Since many gene transfer proto-
cols introduce foreign transgenes, this aspect of the immune 
system may or may not be beneficial, depending on the intended 
outcome of the therapy. For example, Tang et al. (1992) were 
the first to demonstrate the utility of gene transfer for deliber-
ate immunization to a transgene product. This approach has 
since proved useful in generating immune responses to infec-
tious disease agents and tumors (Robinson et al, 1993; 
Yankauckas et al, 1993; Raz et al, 1994; Davis et al, 1995; 
Michel et al, 1995; Mor et al, 1995; Huygen et al, 1996; 
Schirmbeck et al, 1996). However, the success of gene trans-
fer strategies designed as replacement therapies to correct ge-
netic disorders may be compromised by the immune response 
to the transgene product. Indeed, numerous reports have veri-
fied that the immune system represents a major obstacle to the 
success of in vivo gene replacement therapies (Kay et al, 1994; 
Blaese et al, 1995; Dwarki et al, 1995; Fang et al, 1995; 
Kozarsky etal, 1996; Riddell etal, 1996; Tripathy etal, 1996; 
Hurwitz et al, 1997). Both conventional and experimental im-
munosuppressive protocols have been employed in an attempt 
to control gene transfer-induced immune responses (Fang et al, 
1995; Kay et al, 1995; DeMatteo et al, 1996; Yang et ai, 
1996). 
Similarly, the success of Rev MlO-based gene therapies 
aimed at protecting T cells from HIV replication is dependent 
on the in vivo persistence of Rev MlO-transduced cells. How-
ever, Rev MlO represents a foreign protein that may be targeted 
by the immune system, possibly leading to the elimination of 
transduced cells. While sequential administrations of Rev MlO-
transduced cells may temporarily replace those cells eliminated 
by the immune system, repeated introduction of the foreign 
transgene would likely amplify the anti-Rev MlO immune re-
sponse. The current study was designed to elucidate parame-
ters of the immune response that may be induced by Rev MlO 
gene transfer, and to assess quantitatively the effects of repeated 
gene transfer on the anti-Rev immune response. W e have pre-
viously reported that the emergence of antigen-specific inter-
leukin 2 (IL-2)-producing helper T lymphocytes (HTLs) reflects 
in vivo immune responses that culminate in inflammation and 
tissue damage (Bishop et al, 1992; DeBruyne et ai, 1993, 
1995). Hence, we employed limiting dilution analysis (LDA) 
techniques to quantify Rev-specific HTLs, and assessed the de-
velopment of Rev-specific antibodies following multiple intra-
muscular injections with a plasmid encoding Rev MlO. In ad-
dition, cotransfer of a plasmid encoding transforming growth 
factor /31 (TGF/31) was employed as an immunosuppressive 
modality aimed at ablating the anti-Rev HTL response. The data 
reveal that HTLs, but not antibodies, are induced by genetic 
vaccination with Rev MlO. Further, these data suggest that 
coadministration of an immunosuppressive gene may enhance 
the efficacy of in vivo gene transfer by inhibiting the H T L re-
sponse to the transgene product. 
MATERIALS AND METHODS 
Mice 
Female BALB/c and C57BL/6 mice between 6 and 12 weeks 
of age were obtained from Charles River Laboratories (Raleigh, 
NC). 
Medium 
The culmre medium used in these studies was Dulbecco's 
modified Eagle's medium ( D M E M ) supplemented with 1.6 m M 
L-glutamine, 0.27 m M L-asparagine, 1.4 m M L-arginine-HCl, 
14 m M folic acid, 10 m M HEPES buffer, 1.0 m M sodium pyru-
vate, penicillin/streptomycin (100 units/ml), 2 % heat-inacti-
vated fetal calf serum (FCS) (all obtained from Life Technolo-
gies, Grand Island, NY), and 5 X 10"^ M 2-mercaptoethanol 
(2-ME; Sigma Chemicals, St. Louis, M O ) . 
Rev MlO genetic vaccination 
The Rev MlO expression plasmid pCMV Rev MlO was con-
structed by inserting die Rev MlO c D N A into the Xbal and 
Pstl sites of pVR1332 T/3. This backbone contains the cy-
tomegalovirus (CMV) enhancer, promoter, and first intron to 
increase expression, the rabbit j8-globin polyadenylation se-
quence, and the kanamycin resistance gene. BALB/c or 
C57BL/6 mice were genetically vaccinated by multiple intra-
muscular injections with p C M V Rev MlO. Plasmid injections 
(100 /Ug of D N A total, 50 yug/hind limb) were administered 2 
weeks apart, and splenocytes were harvested 10 days follow-
ing the last plasmid injection. Where indicated, p C M V Rev 
MlO was admixed with an equal concentration of VR1012 
TGF^, which encodes the active form of human TGF/31. The 
VRI0I2 backbone contains the C M V enhancer, promoter, and 
first intron to increase expression, the bovine growth hormone 
polyadenylation sequence, and the kanamycin resistance gene. 
Where indicated, mice were immunized with the control plas-
mid VRI012 /3-gal, which encodes /3-galactosidase. 
Proliferative responses to Rev 
Splenocytes (2 X 10^) obtained from naive or pCMV Rev 
MlO-immunized mice were added to microtiter plates witii vary-
ing concentrations of recombinant Rev protein (kindly provided 
by J. Lee, University of Texas Medical Branch, Galveston, TX). 
Microculmres were incubated for 7 days including a terminal 16-
hr pulse with [̂ Hjthymidine. Cultures were harvested onto fiber 
filter mats and [̂ Hlthymidine incorporation was determined us-
ing a Wallac (Gaidiersburg, M D ) 1205 Betaplate scintillation 
counter. Data are represented as the stimulation index, which is 
calculated as counts per minute (cpm) of responder cells -\- re-
combinant Rev protein/cpm of responder cells only. 
Limiting dilution analysis for lL-2-producing 
helper T lymphocytes 
A conventional LDA technique (Bishop and Orosz, 1989) 
was employed to enumerate Rev-reactive IL-2-producing 
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HTLs. Appropriate dilutions of cell suspensions were added as 
responder cells to microtiter wells along with irradiated (5000 
rad) syngeneic splenocytes as a source of antigen-presenting 
cells and recombinant Rev protein (0.1 /ug/ml). After a 16-hr 
incubation, 1 X 10^ CTLL-20 cells (an IL-2-dependent cell 
line) were added. Microcultures were incubated an additional 
24 hr, including a 16-hr terminal pulse with [^Hjthymidine be-
fore harvesting by aspiration. [^HjThymidine incorporation was 
determined on a Wallac 1205 Betaplate scintillation counter. 
Individual microcultures were considered positive for IL-2 pro-
duction if [^H]thymidine incorporation exceeded the mean plus 
3 S D of [^H]thymidine incorporation in microcultures lacking 
responder cells. 
The CTLL-20 cells used in this assay are maintained on re-
combinant human IL-2 (200 U/ml; provided by C. Reynolds, 
NCI, Rockville, M D ) and do not respond to IL-4. Further, ad-
dition of anti-IL-2 monoclonal antibody (MAb) S4B6.31 elim-
inates CTLL-20 proliferation in the H T L L D A . Thus, this H T L 
L D A is specific for IL-2-producing HTLs and does not detect 
IL-4-producing HTLs. 
Limiting dilution analysis for Rev-reactive 
proliferating T lymphocytes 
The LDA was employed to quantify cells capable of prolif-
erating in response to recombinant Rev in the presence of IL-
2. Dilutions of responder cells were added to microtiter plates 
with 2 X 10^ irradiated syngeneic splenocytes plus 1 0 % FCS, 
recombinant human IL-2 (10 U/ml), and recombinant Rev pro-
tein (0.1 pgjml). Microcultures were incubated for 7 days in-
cluding a 16-hr terminal pulse with [^Hjthymidine before har-
vesting by aspiration onto fiber filter mats. [^H]Thymidine 
incorporation was assessed on a Wallac 1205 Betaplate scintil-
lation counter. Microcultures were considered positive for pro-
liferation if [^H]thymidine incorporation exceeded the mean 
plus 3 S D of [^H]thymidine incorporation in microcultures lack-
ing recombinant Rev. 
Data analysis 
Minimal estimates of Rev-specific HTLs and proliferating T 
lymphocytes (PTLs) frequencies were obtained according to the 
Poisson distribution equation as the slope of a line relating the 
number of responder cells per microwell (plotted on a linear x 
axis) and the percentage of microwells that failed to produce 
IL-2 or proliferate (plotted on a logarithmic y axis). The slope 
of this regression line was determined by computer, using chi-
square minimization analysis as described by Taswell (1981). 
This analysis yields the minimal frequency estimate, the 9 5 % 
confidence interval of the frequency estimate, and a chi-square 
estunate of probability. Frequency estimates with nonoveriap-
ping 9 5 % confidence intervals are statistically significant. 
ELISA for Rev-reactive antibodies 
Dilutions of sera (100 pi) were added in tiiplicate to plates 
coated with recombinant Rev protein (1 /ig/ml). Anti-Rev IgGi 
monoclonal antibody (Advanced Biotechnologies, Columbia, 
M D ) served as a positive contiol. After a 2-hr incubation at 
37°C, plates were washed three times with phosphate-buffered 
saline (PBS) containing 1 % bovine serum albumin (BSA). One 
hundred microliters of biotin-conjugated isotype-specific sec-
ondary antibodies (1 /u.g/ml) was added and plates were incu-
bated at 37°C for 1 hr. These secondary rat anti-mouse IgM and 
IgG antibodies were obtained from The Binding Site (San 
Diego, CA). Plates were washed three times and 100 pi of 
avidin-peroxidase (1.7 /ag/ml) (Sigma Chemicals) were added. 
After a 30-min incubation at room temperature, plates were 
washed three times and 100 pi of A B T S [2,2'-azino-bis(3-eth-
ylbenzthiazoline-6-sulfonic acid)] substî ate (Sigma Chemicals) 
was added to each well. After 30 min, absorbance was deter-
mined at 405 n m with an E L 312e microplate reader (Bio-Tek 
Instruments, Winooski, VT). 
Cytokine ELISA 
Splenocytes obtained from mice immunized with pCMV Rev 
M l O were stimulated in vitro at a concentration of lOVml with 
recombinant Rev (0.1 /ig/ml). Supematants (SNs) were har-
vested at 24 and 72 hr. In some experiments, splenocytes were 
stimulated with Rev for 5 days, then restimulated with Rev in 
fresh medium for an additional 72 hr prior to harvesting SN. 
S N (100 /j,l) was added in triplicate to plates coated with rat 
anti-mouse interferon ^(IFN-y), IL-4, or IL-10 capture anti-
bodies (5 /Lig/ml; PharMingen, San Diego, C A ) . Standards were 
employed by preparing twofold dilutions of murine recombi-
nant IFN-y, IL-4, and IL-10 (PharMingen), with starting con-
centrations of 25, 2.5, and 10 ng/ml, respectively. After a 1-hr 
incubation at room temperature, plates were washed three times 
with 0.05% Tween in PBS. One hundred microliters of rat anti-
mouse secondary biotinylated antibodies (1 /ng/ml; PharMin-
gen) were then added, and plates were incubated at room tem-
perature for 45 min. Plates were then washed three times with 
0.05% Tween in PBS, and 100 fil of avidin-peroxidase (Sigma 
Chemicals) were added. After a 30-min incubation at room tem-
perature, plates were washed three times with 0.05% Tween in 
PBS, and 100 pi of A B T S substrate (Sigma Chemicals) were 
then added to each well. After 30 min, absorbance was deter-
mined at 405 n m with an E L 312e microplate reader (Bio-Tek 
Instruments). Sample cytokine concentiations were calculated 
from a standard curve. The sensitivity of this assay is approx-
imately 300 pg/ml for IFN-y, 100 pg/ml for IL-4, and 150 pg/ml 
for IL-10. 
T cell subset depletion 
Splenocytes were depleted of CD4"'" or CD8"^ T cells prior 
to addition to H T L L D A microcultures by complement-medi-
ated cytolysis. Briefly, 1 X 10^ splenocytes/ml were incubated 
for 1 hronicewitha 1:100 dilution of either anti-CD4(GK1.5) 
or anti-CD8 (2.43) M A b purified from ascites. Splenocytes 
were then pelleted, resuspended in Low-Tox-M rabbit comple-
ment (Accurate Chemicals, Westbury, N Y ) diluted 1:10, and 
incubated for 1 hr at 37°C. Cells were washed three times and 
resuspended to the appropriate viable cell number for use as re-
sponder cells in L D A . Depletion of T cell subsets was verified 
by flow cytometry (FACScan; Becton Dickinson, Mountain 
View, C A ) using fluorescein isothiocyanate (FITC)-conjugated 
anti-CD3, -CD4, and -CDS M A b s (PharMingen), which re-
vealed that the targeted subset represented < 2 % of the resid-
ual splenocyte population. T cell subset depletion versus M A b 
coating was verified by staining with FTTC-conjugated goat 
anti-rat IgG (Jackson ImmunoResearch Laboratories, West-
grove, PA). 
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RESULTS Table 2. Appearance of Rev-REAcrivE 
HTLs Following Genetic Immunization" 
Experimental system 
To identify immune parameters induced by genetic vaccina-
tion with Rev MlO, BALB/c mice were given intramuscular in-
jections with the Rev MlO-encoding plasmid p C M V Rev MlO. 
Multiple plasmid injections were administered 2 weeks apart in 
an attempt to induce a vigorous anti-Rev immune response. 
Splenocytes were harvested 10 days following the last plasmid 
injection and assessed for responsiveness to recombinant Rev 
protein in a variety of immunologic assays. Hence, while mice 
were genetically immunized with Rev MlO, in vitro assays em-
ployed Rev as the antigen. 
Rev-driven proliferative responses 
As shown in Table 1, splenocytes obtained from mice given 
three genetic immunizations with p C M V Rev MlO, but not from 
naive animals, proliferated vigorously in response to recombi-
nant Rev protein. A kinetic study revealed that Rev-driven pro-
liferative responses were detectable following the second in-
tramuscular injection with p C M V Rev MlO, and peaked 
following the third (data not shown). Dose-response studies 
(Table 1) demonstrated that in vitro concentrations of recom-
binant Rev as low as 0.05 /ig/ml were sufficient to drive im-
mune T cell proliferation (simulation index [SI] of 15.2), but 
did not induce proliferation of naive cells (SI of 1.8). Given 
these observations, recombinant Rev was used at 0.1 /xg/ml for 
subsequent in vitro assays. 
Rev-reactive helper T lymphocytes responses 
The Rev-driven proliferative responses illustiated in Table 1 
were detected without the addition of exogenous IL-2 to the 
culture system. This suggested that Rev-reactive helper T lym-
phocytes (HTLs) developed after immunization with p C M V 
Rev MlO, which in tum provided the necessary growth factors 
for clonal expansion of Rev-reactive T cells. W e have previ-
ously demonstrated that the presence of IL-2-producing HTLs 
Table 1. Proliferative Responses Following 
Rev M l O Genetic Immunization" 
Naive splenocytes 
Rev M l O immune splenocytes 
Stimulation index 
Rev (/Jig/ml) 
10 0.5 0.05 
2.5 3.9 1.8 
25.8 15.4 15.2 
"BALB/c mice received three biweekly intramuscular 
injections of 100 /xg of plasmid encoding Rev MlO. Ten days 
after the third injection, splenocytes were processed and 
cultured at 1 X 10* cells/ml in 200-/xl volumes for 5 days with 
varying concentrations of recombinant Rev protein. Cultures 
received a terminal 18-hr pulse with 0.5/xCi of [̂ H] thymidine 
prior to harvesting for scintillation counting. Data are reported 
as the stimulation index, which is calculated as the mean counts 
per minute of cultures stimulated with Rev divided by the mean 
counts per minute of cultures without Rev stimulation. 










































"BALB/c mice were given varying numbers of biweekly 
intramuscular injections of 100 /xg of plasmid encoding 
Rev MlO. Ten days after the indicated number of injections, 
splenocytes were processed for use as responder cells in 
Rev-reactive H T L and PTL LDAs. 
''Splenocytes were harvested 6 weeks after the fourth Rev 
M l O plasmid immunization. 
'̂ As a plasmid control, mice were given four biweekly 
immunizations with a plasmid encoding /3-galactosidase. 
Abbreviations: HTL, Helper T lymphocyte; PTL, proliferating 
T lymphocyte. 
best reflects the ability to mount a deleterious immune response 
following cardiac transplantation in both mice (Bishop et al, 
1992) and humans (DeBruyne et al, 1993, 1995). Hence, we 
adapted our previously described limiting dilution analysis 
(LDA) technique (Bishop and Orosz, 1989) to quantify Rev-re-
active IL-2-producing HTLs. 
Initial studies evaluated the kinetic appearance of Rev-reac-
tive HTLs in the spleens of BALB/c mice following muhiple 
biweekly injections with p C M V Rev MIO. As shown in Table 
2, Rev-reactive HTLs were rare or not detectable in the spleens 
of naive mice (1/189,907). However, Rev-reactive HTLs ap-
peared following the second immunization with p C M V Rev 
M l O and leveled off over the diird and fourth plasmid injec-
tions. This induction of Rev-reactive HTLs by p C M V Rev M l O 
immunization has been observed in more tiian 20 separate ex-
periments, with the frequency of Rev-reactive HTLs ranging 
from approximately 1/1000-1/15,000. In addition, these Rev-
reactive HTLs persisted in the spleens of mice for at least 6 
weeks following the fourth genetic immunization (Table 2). As 
an additional negative control, mice received 4 intt-amuscular 
injections with a plasmid encoding /3-galactosidase. Immu-
nization with this /3-galactosidase plasmid failed to induce a 
significant frequency of Rev-reactive HTLs (Table 2). Finally, 
it should be noted that the ability to mount a Rev-reactive H T L 
response is not unique to the BALB/c mouse, in that C57BL/6 
mice immunized with p C M V Rev M l O developed similar H T L 
responses (data not shown). 
Table 2 also illustiates the frequency of proliferating T lym-
phocytes (PTLs) in L D A microcultures that are supplemented 
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Table 3. Presence of Rcv-Reactive IL-2-Producing 

































"BALB/c mice received three to four biweekly intramuscular injections of a 
plasmid encoding Rev MlO. Ten days after the last immunization, splenocytes 
were harvested and used as responder cells in an Rev-reactive H T L LDA, or 
cultured at IX 10* cells/ml in the presence of 0.1 /xg of Rev/ml. Supematants 
were harvested at 72 hr and IFN-y, IL-4, and IL-10 concentrations were BALB/c 
splenocytes stimulated witii 1 /xg of ConA/ml for 72 hr. 
''ND, Not detectable. 
with exogenous IL-2. This PTL L D A is designed to quantify 
the number of cells capable of proliferating in response to a 
given antigen when exogenous growth factors are provided. In 
contrast to HTLs, PTLs were detectable in naive mice 
(1/20,009), although they increased in number following p C M V 
Rev M l O immunization. These data suggest tiiat while precur-
sor cells with the potential to respond to Rev are present in 
naive animals at appreciable frequencies, the limiting factor in 
mounting an anti-Rev immune response is the IL-2-producing 
HTL. Further, these data indicate that monitoring H T L fre-
quencies may be used as a sensitive indicator of an Rev MIO-
induced response. 
Failure to detect additional cytokine production by 
Rev-reactive T cells 
W e also assessed the ability of splenocytes obtained from 
p C M V Rev MlO-immunized mice to produce IFN-y, IL-4, and 
IL-10. Briefly, immune splenocytes were cultured at 1 X 
10*/ml in the presence or absence of recombinant Rev (0.1 
/xg/ml). Culture supematants were harvested at 24 and 72 hr 
and assessed for cytokine content by standard enzyme-linked 
immunosorbent assay (ELISA). The results of three separate 
experiments are depicted in Table 3. Despite the presence of 
IL-2-producing HTLs, IL-4 and IL-10 were not detectable by 
ELISA, and IFN-y concentrations were low or not detectable. 
In additional experiments, immune splenocytes were cultured 
witii Rev for 5 days, then restimulated with Rev in fresh medium 
for an additional 72 hr. Cytokine production in these secondary 
cultures was also not detectable (data not shown). Hence, while 
p C M V Rev M l O immunization induced IL-2-producing HTLs 
that were readily detectable by LDA, ELISAs failed to detect 
the production of additional cytokines by immune T cells. 
Phenotype of Rev-reactive helper T lymphocytes 
Since IL-2-producing HTLs are CD4+ T cells in many (but 
not all) systems, we depleted CD4+ or CD8+ cells following 
the tiiird immunization with p C M V Rev MlO and quantified 
Rev-reactive HTLs in die selected populations by LDA. As 
shown in Table 4, depletion of CD4"'" cells markedly reduced 
the frequency of Rev-reactive HTLs (1/16,838 -^ 1/52,942), in-
dicating that the majority of HTLs were CD4+. Further, de-
pletion of C D 8 ^ cells increased the frequency of Rev-reactive 
HTLs (1/5728), likely reflecting the enrichment for CD4+ cells 
following removal of the CDS"^ population. 
TGFpi gene transfer inhibits Rev-reactive helper T 
lymphocyte development 
W e next asked if the immune response induced by p C M V 
Rev MlO immunization could be circumvented by cotransfec-
tion with plasmids encoding immunosuppressive agents. To this 
end, BALB/c mice received three immunizations with either 
p C M V Rev MlO alone, or p C M V Rev MlO plus a plasmid en-
coding the active form of human TGF/31. The frequencies of 
Rev-reactive IL-2-producing HTLs in the spleens of these mice 
are shown in Table 5. As described above, immunization with 
p C M V Rev MlO alone resulted in the development of readily 
detectable Rev-reactive HTLs (1/11,973). Interestingly, co-
transfection with a plasmid encoding the immunosuppressive 
Table 4. Phenotype of Rcv-Reactive 
IL-2-Producing HTLs" 












"BALB/c mice received three biweekly intramuscular 
injections of 100 /xg of plasmid encoding Rev MlO. Ten days 
after the third immunization, splenocytes were harvested and 
depleted of eidier CD4+ or CD8"^ T cells, or left untreated. Re-
sulting populations were used as responder cells in an 
Rev-reactive H T L LDA. 
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Table 5. TGF/Sl Gene Cotransfer Inhibits 










"BALB/c mice received three biweekly intramuscular 
injections of either 100 /xg of plasmid encoding Rev MlO or a 
mixture of 100 /xg of plasmid encoding Rev MlO plus 100 pg 
of plasmid encoding the active form of human TFG/31. Ten 
days after the third injection, splenocytes were isolated for use 
as responder cells in an Rev-reactive H T L LDA. 
cytokine TGFjSl markedly decreased the frequency of Rev-re-
active HTLs (1/130,389). Hence, while gene transfer strategies 
may induce an immune response, these responses may be tem-
pered by cotransfer of genes encoding appropriate immuno-
suppressive agents. 
Rev M l O gene transfer does not induce detectable IgG 
antibody production 
Since a vigorous H T L response was induced following ge-
netic vaccination with Rev MlO, we asked whether these HTLs 
provided help for the production of anti-Rev antibodies. An 
ELISA was employed to detect Rev-reactive IgG and IgM in 
the sera of mice that had received three injections with p C M V 
Rev MlO (Fig. 1). In more than 10 separate experiments. Rev-
reactive IgG antibodies were not detectable by ELISA. While 
low levels of Rev-reactive IgM antibodies were detectable in 
the sera of p C M V Rev MlO-immunized mice, similar levels of 
these IgM antibodies were present in the sera of naive mice 
(Fig. 1). One possible explanation for these negative results was 
that the recombinant Rev protein used to coat the ELISA plate 
did not adhere effectively to the plate. To test this possibility, 
varying concentrations of an anti-Rev IgGi M A b were used as 
the primary antibody in the ELISA. As shown in Fig. 1, reac-
tivity with the anti-Rev M A b was readily demonstrable, veri-
fying the utility of this Rev ELISA in detecting anti-Rev anti-
bodies. Finally, to demonstrate that BALB/c mice could mount 
a detectable anti-Rev IgG response, we immunized animals in-













'/. 2 U .ZbcL a 
Rev mAb 
Hg/mL 
1:10 1:20 1:40 
Rev Plasmid 
Immunization 
1:10 1:20 1:40 
No 
Immunization 
1:10 1:20 1:40 
Rev Protein+ C.F.A 
Immunization 
M o u s e Serum Dilutions 
FIG. 1. Rev MlO genetic vaccination does not induce the production of IgG antibodies. An ELISA was used to measure Anti-
Rev antibodies in dilutions of sera obtained from BALB/c mice 10 days after the third intramuscular injection of the Rev MlO-
encoding plasmid p C M V Rev MlO (see Materials and Methods). ELISA detection antibodies were specific for either mouse IgM 
or IgG. A Rev-specific IgGi M A b served as a positive control. Results are compared with tiiose obtained from the sera of naive 
mice, and with the sera of mice 21 days following intraperitoneal immunization with 100 /xg of recombinant Rev in Freund's 
complete adjuvant. 
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juvant. As shown in Fig. 1, these mice mounted a sti-ong anti-
Rev IgG response by day 21 postimmunization. 
DISCUSSION 
The efficacy of in vivo gene ti-ansfer stiategies is limited by 
the relative immunogenicity of both the transgene product and 
the vector employed to facilitate ti-ansfection. Gene tiansfer-in-
duced immune responses may eliminate transfected cells, 
thereby limiting duration of transgene expression. Further, lo-
cal inflammation induced by the transgene product and/or vec-
tor within transfected tissues may compromise normal tissue 
function, thereby exacerbating, rather than alleviating, the orig-
inal disease process. The current study focused on the immune 
response induced by in vivo inttoduction of the anti-HIV gene. 
Rev MlO. Transfection of human T cells with Rev M l O ren-
ders these cells resistant to HIV replication in vitro (Bevec et 
al, 1992; Malim et al, 1992; Woffendin et al, 1994), and cells 
that have been retrovhally ttansduced with Rev M l O may per-
sist for extended periods when reintroduced into HIV-infected 
individuals in vivo (Ranga et al, 1998). Nonetiieless, the ef-
fects of the immune response on the long-term survival and 
function of Rev MlO-ttansduced cells have not been estab-
lished, and may negatively influence the efficacy of this anti-
HIV gene therapy. Indeed, Riddell et al. (1996) reported that T 
cells that expressed a foreign selection marker were eliminated 
by the immune response to the ttansgene product when these 
cells were inttoduced into HIV-infected individuals. To date, 
the potential immunogenicity of Rev M l O gene transfer has not 
been rigorously explored. Hence, mice were deliberately im-
munized by repeated inttamuscular administrations of plasmid 
encoding Rev M l O in an attempt to define immune parameters 
that could be mobilized by Rev M l O gene transfer. 
Studies that have assessed the cellular immune responses to 
Rev are limited. Blazevic etal. (1995) attempted to identify im-
munogenic regions of Rev by evaluating the ability of poly-
clonal T cell lines obtained from HIV-infected individuals to 
incorporate deoxyuridine when stimulated with synthetic Rev 
peptides. Several peptides approximately 15 amino acids in 
length had stimulatory activity for polyclonal T cell lines ob-
tained from some, but not all, individuals. Weak cytotoxic T 
lymphocyte (CTL) responses were also detectable when autol-
ogous Epstein-Barr virus (EBV)-transformed B cells were 
pulsed with these peptides and used as C T L target cells. How-
ever, responses were quite variable, and the majority of indi-
viduals failed to respond to any ofthe 13 peptides tested (Blaze-
vic et al, 1995). Similar to our study. Shiver et al. (1995) 
reported that vaccination of mice with a Rev-encoding plasmid 
generated cells that proliferated in response to recombinant Rev 
protein in vitro. Further, Shiver et al. stated that IFN-y, but not 
IL-4, was produced when splenocytes from plasmid-vaccinated 
mice were stimulated with Rev in vitro. However, the amount 
of IFN-y produced by these cells was not presented. In the cur-
rent study, we assessed Rev-induced production of IFN-y, IL-
4, and IL-10 by splenocytes obtained from mice following mul-
tiple immunizations with Rev MlO-encoding plasmids (Table 
3). IL-4 and IL-10 were not detectable by ELISA in the super-
natants of these Rev-stimulated splenocytes, and IFN-y pro-
duction was lunited or not detectable. It should be noted that 
plasmid p C M V Rev M l O used in our study contains a 
kanamycin resistance gene, while the Rev-encoding plasmid 
employed by Shiver et al. was derived from pUC19, which con-
tains an ampicillin selection marker. Sato et al. (1996) reported 
that the unmethylated C p G motifs present in the ampicillin, but 
not the kanamycin, resistance gene promote the development 
of IFN-y-producing helper T cell type 1 (Thi) cells following 
D N A vaccination. Hence, differences in the Rev-induced W N -
y response observed in our study and that of Shiver et al. may 
reflect differences in the C p G content ofthe plasmids employed. 
Altematively, differences may be attributed in part to the use 
of plasmids encoding wild-type Rev versus Rev MlO. How-
ever, it should be noted that Rev M l O differs from wild-type 
Rev by only two amino acid substitutions (Malim et al, 1991). 
The impact of this difference on the immune response to Rev 
has not been defined. 
Like Shiver et al. (1995), we found that Rev M l O gene ttans-
fer induced a vigorous proliferative response to Rev (Table 1). 
This response was observed when splenocytes from immunized, 
but not naive, mice were cultured at high cell concenttation 
( I X 10^/ml) in the presence of recombinant Rev. Proliferation 
in these bulk cultures suggested that cells capable of producing 
IL-2 or other T cells growth factors were induced by Rev M l O 
genetic immunization. In addition, P T L L D A revealed that cells 
with the potential to proliferate to Rev were readily detectable 
in both immunized and naive mice (Table 2). Since the P T L 
L D A employed in this study is supplemented with exogenous 
IL-2, this observation suggested that a limiting factor in the 
ability of naive cells to respond to Rev was a requirement for 
Rev-reactive IL-2 producing cells. Indeed, we (Bishop et al, 
1992; DeBruyne et al, 1993, 1995) and others (Theobald et al, 
1992) have reported that the presence of IL-2-producing H T L 
reflects the ability of an individual to mount a clinically sig-
nificant immune response to alloantigens. As predicted, Rev-
reactive HTLs were not present in naive mice, but appeared fol-
lowing two genetic immunizations with p C M V Rev M l O (Table 
2). 
The observation that Rev-reactive H T L s were CD4''- (Table 
4) is of interest. Rev is a DNA-binding protein and therefore 
is not actively secreted. Hence, the Rev M l O transgene prod-
uct should not be readily available for presentation to CD4-'-
cells via the class II antigen presentation pathway (reviewed 
by Braciale and Braciale, 1991). Given the cellular localiza-
tion of Rev, one might predict that gene transfer of Rev M l O 
would preferentially stimulate CDS'"- T cells via class I anti-
gen presentation. However, we were unable to detect Rev-re-
active CDS"^ CTLs, using established L D A techniques (Orosz 
et al, 1989; Bishop et al, 1992; Nabel et al, 1996) with Rev 
MlO-ttansduced R E N C A cells serving as C T L targets (data not 
shown). Nonetheless, CD4-'- H T L s were reproducibly induced 
by p C M V Rev M l O immunization, indicating that the ttans-
gene product entered the class II antigen presentation pathway. 
However, genetic vaccination did not stimulate an anti-Rev an-
tibody response (Fig. 1), indicating that the transgene product 
was not available for recognition by B cells. Shiver et al. (1995) 
also reported that genetic immunization with Rev failed to elicit 
an antibody response. It should be noted that Rev may induce 
an antibody response in both HIV-infected individuals (Devash 
et al, 1990) and in mice immunized with Rev protein (Fig. 1 
and VoU et al, 1990). Hence, the mode of delivery of Rev ap-
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pears to influence the scope of the response that is elicited. 
Others have reported that the nature of a ttansgene-induced re-
sponse may be influenced by the route of D N A administration 
and by the tissue and cell types that are transfected. For ex-
ample, Raz et al. (1994) reported an antibody, rather than a 
cellular response, was induced when the transgene was intro-
duced intradermally, as opposed to intramuscularly. Similarly, 
Feltquate et al. (1997) reported that a Thi response is prefer-
entially induced by a transgene product when plasmids are in-
ttoduced in saline. In contrast, gene gun delivery of the D N A 
preferentially induces a Th2 response to the ttansgene prod-
uct. Aspects of the immune response induced by the introduc-
tion of Rev MlO-transduced hematopoietic cells in humans 
have not been defined, and are currentiy being explored in our 
laboratory. 
Several immunosuppressive strategies have been explored as 
a means to inhibit the immune response to both transgene prod-
ucts and viral vectors. These include inhibitors of cytokine syn-
thesis such as cyclosporin A (Fang et al, 1995), blockade of 
costimulatory pathways with either CTLA4Ig (Kay et al, 1995) 
or anti-CD40 ligand M A b (Yang et al, 1996), and ttansient de-
pletion of C D 4 + T cells (DeMatteo et al, 1996). In addition, 
coadministtation of genes encoding immunosuppressive agents 
shows promise as an altemate approach to control gene trans-
fer-induced responses. Examples of this strategy include the 
ttansfer of genes encoding immunosuppressive proteins of the 
E3 region of adenovirus (Lee et al, 1995; llan et ai, 1997), 
IL-1 receptor antagonist (McCoy et ai, 1995), and the E B V 
product viral IL-10 (Qin et al, 1997). Our observation that co-
transfer of a plasmid encoding the active form of human TGF/31 
ablates the H T L response induced by Rev M l O genetic vacci-
nation (Table 5) further supports the utility of "genetic im-
munosuppression" in the management of ttansgene-induced im-
mune responses. TGF/31 is a pleiotrophic cytokine that mediates 
multiple antiinflammatory activities (Wahl, 1994), including in-
hibition of Thi responses (Schmitt et al, 1994), E-selectin ex-
pression by endothelial cells (Gamble et ai, 1993), and C T L 
development (Inge et al, 1992). However, excess production 
or systemic administration of TGF/31 has been associated with 
unresolved inflammation and fibrosis (Border and Ruoslahti, 
1992; Wahl, 1994). It should be noted that no adverse effects 
were observed when mice received intramuscular injections of 
plasmid encoding TGF/31 in this study. Parameters assessed in-
cluded physical activity, weight loss, coat condition, and 
splenomegaly. Hence, local delivery of TGF/31 via plasmid in-
oculation provided the desired immunosuppressive effect with-
out overt toxicity. 
To our knowledge, this study represents the first to quantify 
IL-2-producing HTLs as an indicator of the immune response 
induced by a plasmid encoding Rev M l O in vivo. W e suggest 
that similar H T L responses may be mounted to other transgene 
products, and that L D A may prove useful in monitoring the 
evolution of gene transfer-induced immune responsiveness in 
the setting of replacement gene therapy and of genetic vacci-
nation. Finally, data from this study support the feasibility of 
combining genes that encode immunosuppressive cytokines 
with the transgene of interest as a modification aimed at in-
hibiting the development of transgene-neutralizing immune re-
sponses. 
ACKNOWLEDGMENTS 
We would like to tiiank Judy Stein for administtative assis-
tance and Dr. James C. Lee of the University of Texas Med-
ical Branch (Galveston, T X ) for generously providing recom-
binant Rev protein for these studies. This work was supported 
by National Institutes of Health Grant AI36606. 
REFERENCES 
BAHNER, I., ZHOU, C, YU, X.-J., HAO, Q.-L., GUATELLI, J.C, 
and KOHN, D.B. (1993). Comparison of trans-domiaant inhibitor 
mutant human immunodeficiency virus type 1 genes expressed by 
retroviral vectors in human T lymphocytes. J. Virol. 67, 3199-3207. 
BEVEC, D., DOBROVNIK, M., HAUBER, J., and BOHNLEIN, E. 
(1992). Inhibition ofhuman immunodeficiency virus type 1 replica-
tion in human T cells by retroviral-mediated gene transfer of a dom-
inant-negative Rev trans-activator. Proc. NaU. Acad. Sci. U.S.A. 89, 
9870-9874. 
BISHOP, D.K., and OROSZ, C O . (1989). Limiting dilution analysis 
for allo-reactive, TCGF-secreting T cells: L D A methods that dis-
criminate between unstimulated precursor T cells and in vivo al-
loactivated T cells. Transplantation 47, 671-677. 
BISHOP, D.K., FERGUSON, R.M., and OROSZ, C G . (1992). Dif-
ferential distribution of antigen specific helper T cells and cytotoxic 
T cells following antigenic stimulation in vivo: A functional study 
using limiting dilution analysis. J. Immunol. 144, 1153-1160. 
BLAESE, R.M., CULVER, K.W., MILLER, A.D., CARTER, C.S., 
FLEISHER, T., CLERICI, M., SHEARER, G., C H A N G , L., CHI-
ANG, Y., TOLSTOSHEV, P., GREENBLATT, J.J., ROSENBERG, 
S.A., KLEIN, H., BERGER, M., MULLEN, C.A., R A M S E Y , W.J., 
M U U L , L., M O R G A N , R.A., and ANDERSON, W.F. (1995). T lym-
phocyte-directed gene therapy for A D A " SCID: Initial trial results 
after 4 years. Science 270, 475^80. 
BLAZEVIC, v., RANKI, A., and K R O H N , K.J.E. (1995). Helper and 
cytotoxic T cell responses of HIV type 1-infected individuals to syn-
thetic peptides of HIV type 1 Rev. AIDS Res. Hum. ReU-oviruses 
11, 1335-1342. 
BORDER, W.A., and RUOSLAHTI, E. (1992). Transforming growth 
factor-/? in disease: The dark side of tissue repair. J. Clin. Invest. 
90, 1. 
BRACIALE, T.J., and BRACIALE, V.L. (1991). Antigen presentation: 
Structural themes and functional variations. Immunol. Today 12, 
124-129. 
CULLEN, B.R., HAUBER, J., CAIVIPBELL, K., SODROSKI, J.C, 
HASELTINE, W.A., and ROSEN, C A . (1988). Subcellular local-
ization of the human immunodeficiency virus trans-acting art gene 
product. J. Virol. 62, 2498-2501. 
DAVIS, H.L., SCHIRMBECK, R., REIMANN. J., and W H A L E N , 
R.G. (1995). DNA-mediated immunization in mice induces a potent 
M H C class I-restricted cytotoxic T lymphocyte responses to the he-
patitis B envelope protein. Hum. Gene Ther. 6, 1447-1456. 
DeBRUYNE, L.A., ENSLEY, R.D., OLSEN, S.L, TAYLOR, D.O., 
CARPENTER, B.M., HOLLAND, C , S W A N S O N , S., JONES, 
K.W., K A R W A N D E , S.V., RENLUND, D.G., and BISHOP, D.K. 
(1993). Increased frequency of alloantigen-reactive helper T lym-
phocytes is associated with human cardiac allograft rejection. Trans-
plantation 56, 722-727. 
DeBRUYNE, L.A., RENLUND, D.G., and BISHOP, D.K. (1995). Ev-
idence that human cardiac allograft acceptance is associated with a 
decrease in donor-reactive helper T lymphocytes. Transplantation 59, 
778-783. 
GENE TRANSFER-INDUCED HELPER T CELLS 2195 
DeMATTEO, R.P., MARKMANN, I.E., KOZARSKY, K.F., 
BARKER, C.F., and RAPER, S.E. (1996). Prolongation of adenovi-
ral transgene expression in mouse liver by T lymphocyte subset de-
pletion. Gene Ther. 3, 4-12. 
DEVASH, Y., REAGAN, K., W O O D , D., TURNER, J., PARRING-
TON, M., and KANG, CY. (1990). Antibodies against AIDS pro-
teins. Nature (London) 345, 581. 
DWARKI, V.J., BELLONI, P., NUJAR, T., SMITH, J., COUTO, L., 
RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). 
Gene therapy for hemophilia A: Production of therapeutic levels of 
human factor Vin in vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92, 
1023-1027. 
FANG, B., EISENSMITH, R.C, W A N G , H., KAY, M.A., CROSS, 
R.E., LANDEN, C.N., GORDON, G., BELLINGER, D.A., READ, 
M.S., HU, P.C, BRINKHOUS, K.M., and W O O , S.L.C. (1995). 
Gene therapy for hemophilia B: Host immunosuppression prolongs 
the therapeutic effect of adenovirus-mediated factor LX expression. 
Hum. Gene Ther. 6, 1039-1044. 
FELTQUATE, D.M., HEANEY, S., WEBSTER, R.G., and ROBIN-
SON, H.L. (1997). Different T helper cell types and antibody iso-
types generated by saline and gene gun DNA immunization. J. Im-
munol. 158, 2278-2284. 
GAMBLE, J.R., KHEW-GOODALL, Y., and VADAS, M.A. (1993). 
Transforming growth factor-/3 inhibits E-selectin expression on hu-
man endothelial cells. J. Immunol. 150, 4494-4503. 
HURWITZ, D.R., KIRCHGESSER, M., MERRILL, W., 
GALANOPOULOS, T., McGRATH, C.A., EMAMI, S., HANSEN, 
M., CHERINGTON, V., APPEL, J.M., BIZINKAUSKAS, C.B., 
BRACKMANN, H.H., LEVINE, P.H., and GREENBERGER, J.S. 
(1997). Systemic delivery of human growth hormone or human fac-
tor IX in dogs by reintroduced genetically modified autologous bone 
marrow stromal cells. Hum. Gene Ther. 8, 137-156. 
HUYGEN, K., CONTENT, J., DENIS, O., MONTGOMERY, D.L., 
Y A W M A N , A.M., DECK, R.R., DEWITT, CM., ORME, I.M., 
BALDWIN, S., D'SOUZA, C, DROWART, A., LOZES, E., VAN-
DENBUSSCHE, P., VAN VOOREN, J.-P., LIU, M.A., and ULMER, 
J.B. (1996). Immunogenicity and protective efficacy of a tuberculo-
sis D N A vaccine. Nature Med. 2, 893-898. 
ILAN, Y., DROGUETT, G., CHOWDHURY, N.R., LI, Y., SEN-
GUPTA, K., THUMMALA, N.R., DAVIDSON, A., CHOWD-
HURY, J.R., and HORWITZ, M.S. (1997). Insertion of the aden-
oviral E3 region into a recombinant viral vector prevents antiviral 
humoral and cellular immune responses and permits long-term gene 
expression. Proc. Natl. Acad. Sci. U.S.A. 94, 2587-2592. 
INGE, T.H., HOOVER, S.K., SUSSKIND, B.M., BARRETT, S.K., and 
BEAR, H.D. (1992). Inhibition of tumor-specific cytotoxic T-lym-
phocyte responses by transforming growth factor /31. Cancer Res. 
52, 1386-1392. 
KAY, M.A., LANDEN, C.N., ROTHENBERG, S.R., TAYLOR, L.A., 
LELAND, F., WIEHLE, S., FANG, B., BELLINGER, D., FINE-
GOLD, M., THOMPSON, A.R., READ, M., BRINKHOUS, K.M., 
and W O O , S.L.C. (1994). In vivo hepatic gene therapy: Complete al-
beit transient correction of factor IX deficiency in hemophilia B dogs. 
Proc. Nad. Acad. Sci. U.S.A. 91, 2353-2357. 
KAY, M.A., HOLTERMAN, A.-X., MEUSE, L., G O W N , A., OCHS, 
H.D., LINSLEY, P.S., and WILSON, C.B. (1995) Long-term hepatic 
adenovirus-mediated gene expression in mice following CTLA4Ig 
administration. Nature Genet. 11, 191-197. 
KOZARSKY, K.F., BONEN, D.K., GIANNONI, F., FUNAHASHI, T., 
WILSON, J.M., and DAVIDSON, N.O. (1996). Hepatic expression 
of the catalytic subunit of the apolipoprotein B m R N A editing en-
zyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-
deficient rabbits. Hum. Gene Ther. 7, 943-957. 
LEE, M.G., ABINA, M.A., H A D D A D A , H., and PERRICAUDET, M. 
(1995). The constitutive expression ofthe immunomodulatory gp 19k 
protein in E1-, E3— adenoviral vectors strongly reduces the host 
cytotoxic T cell response against the vector. Gene Ther. 2, 256-262. 
LIU, J., WOFFENDIN, C, YANG, Z.-Y., and NABEL, G.J. (1994). 
Regulated expression of a dominant negative form of Rev improves 
resistance to HIV replication in T cells. Gene Ther. 1, 32-37. 
MALIM, M.H., BOHNLEIN, S., HAUBER, J., and CULLEN, B.R. 
(1989). Functional dissection of the HIV-1 Rev fran.5-activator-de-
rivation of a rra«i-dominant repressor of Rev function. Cell 58, 
205-214. 
MALIM, M.H., McCARN, D.F., TILEY, L.S., and CULLEN, B.R. 
(1991). Mutational definition of the human immunodeficiency virus 
type 1 Rev activation domain. J. Virol. 65, 4248-4254. 
MALIM, M.H., FREIMUTH, W.W., LIU, J., BOYLE, T.J., LYERLY, 
H.K., CULLEN, B.R., and NABEL, G.J. (1992). Stable expression 
of transdominant Rev protein in human T cells inhibits human im-
munodeficiency virus replication. J. Exp. Med. 176, 1197-1201. 
McCOY, R.D., DAVIDSON, B.L., ROESSLER, J., HUFFNAGLE, 
B.B., and SIMON, R.H. (1995). Expression of human interieukin-1 
receptor antagonist in mouse lungs using a recombinant adenovirus: 
Effects on vector-induced inflammation. Gene Ther. 2, 437-442. 
MICHEL, M.-L., DAVIS, H.L., SCHLEEF, M., MANCINI, M., TIOL-
LAIS, P., and WHALEN, R.G. (1995). DNA-mediated immuniza-
tion to the hepatitis B surface antigen in mice: Aspects of the hu-
moral response mimic hepatitis B viral infection in humans. Proc. 
Natl. Acad. Sci. U.S.A. 92, 5307-5311. 
MOR, G., KLINMAN, D.M., SHAPIRO, S., HAGIWARA, E., SEDE-
GAH, M., N O R M A N , J.A., HOFFMAN, S.L., and STEINBERG, 
A.D. (1995). Complexity of the cytokine and antibody response 
elicited by immunizing mice with Plasmodium yoelii circumsporo-
zoite protein plasmid DNA. J. Immunol. 155, 2039-2046. 
NABEL, G.J., GORDON, D., BISHOP, D.K., NICKOLOFF, B.J., 
YANG, Z.-Y., ARUGA, A., CAMERON, M.J., NABEL, E.G., and 
CHANG, A.E. (1996). Immune response in human melanoma after 
transfer of an allogeneic class I major histocompatibility complex 
gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. U.S.A. 
93, 15388-15393. 
QIN, L, DING, Y., PAHUD, D.R., ROBSON, N.D., SHAKED, A., 
and BROMBERG, J.S. (1997). Adenovirus-mediated gene transfer 
of viral IL-10 inhibits the immune response to both alloantigen and 
adenoviral antigen. Hum. Gene Ther. 8, 1365-1374. 
RANGA, U., WOFFENDIN, C, VERMA, S., XU, L., JUNE, C.H., 
BISHOP, D.K., and NABEL, G.J. (1998). Enhanced T cell engraft-
ment after retroviral delivery of an antiviral gene in HIV-infected in-
dividuals. Proc. Natl. Acad. Sci. U.S.A. 95, 1201-1206. 
RAZ, E., CARSON, D.A., PARKER, S.E., PARR, T.B., ABAI, A.M., 
AICHINGER, G., GROMKOWSKI, S.H., SINGH, M., LEW, D., 
YANKAUCKAS, M.A., BAIRD, S.M., and RHODES, G.H. (1994). 
Intradermal gene immunization: The possible role of D N A uptake in 
the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. 
U.S.A. 93,5141-5145. 
RIDDELL, S.R., ELLIOT, M., LEWINSOHN, D.A., GILBERT, M.J., 
WILSON, L., MANLEY, S.A., LUPTON, S.D., OVERELL, R.W., 
REYNOLDS, T.C, COREY, L., and GREENBERG, P.D. (1996). 
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T 
lymphocytes in HIV-infected patients. Nature Med. 2, 216-223. 
ROBINSON, H.L., HUNT, L.A., and WEBSTER, R.G. (1993). Pro-
tection against a lethal influenza virus challenge by immunization 
with a hemagglutinin-expressing plasmid DNA. Vaccine 11, 
957-960. 
SATO, Y., ROMAN, M., TIGHE, H., LEE, D., CORR, M., NGUYEN, 
M.-D., SILVERMAN, G.J., LOTZ, M. CARSON, D.A,, and RAZ, 
E. (1996). Immunostimulatory DNA sequences necessary for effec-
tive intradermal gene immunization. Science 273, 352-354. 
SCHIRMBECK, R., BOHM, W., and REIMANN, J. (1996). DNA vac-
cination primes M H C class I-restricted, simian virus 40 large tumor 
2196 CHAN ET AL. 
antigen-specific CTL in H-2d mice that reject syngeneic tumors. J. 
Immunol. 157, 3550-3558. 
SCHMIIT, E., HOEHN, P., HUELS, C, GOEDERT, S., PALM, N., 
RUDE, E., and GERMANN, T. (1994). T helper type 1 development 
of naive CD4-I- T cells requires the coordinate action of interleukin-
12 and interferon-y and is inhibited by transforming growth factor-
j3. Eur. J. Immunol. 24, 793-798. 
SHIVBR, J.W., PERRY, H.C, DAVIES, M.-E., FREED, D.C, and 
LIU, M.A. (1995). Cytotoxic T lymphocyte and helper T cell re-
sponses following HIV polynucleotide vaccination. Ann. N.Y. Acad. 
Sci. 772, 198-208. 
SODROSKI, J., GOH, W.C, ROSEN, C, DAYTON, A., TER-
WILLIGER, E., and HASELTINE, W. (1986). A second post-tran-
scriptional ?ra«i-activator gene required for HTLV-IH replication. 
Namre (London) 321, 412^17. 
TANG, D.-C, DEVir, M., and JOHNSTON, S.A. (1992). Genetic im-
munization is a simple method for eliciting an immune response. Na-
ture (London) 356, 152-154. 
TASWELL, C (1981). Limiting dilution assays for the determination 
of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 
126, 1614-1619. 
THEOBALD, M., NIERLE, T., BUNJES, D., ARNOLD, R., and 
HEIMPLE, H. (1992). Host-specific interleukin-2-secreting donor T-
cell precursors as predictors of acute graft-versus-host disease in bone 
marrow transplantation between HLA-identical siblings. N. Engl. J. 
Med. 327, 1613-1617. 
TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, 
J.M. (1996). Immune responses to transgene-encoded proteins limit 
the stability of gene expression after injection of replication-defec-
tive adenovirus vectors. Nature Med. 2, 545—550. 
VOLL, R., AEPINUS, C, KRAPF, F., HERRMANN, M., KALDEN, 
J.R., and FLECKENSTEIN, B. (1990). Monoclonal antibodies di-
rected against the Rev protein of human immunodeficiency virus type 
1. Mol. Cell. Prob. 4, 63-72. 
W A H L , S.M. (1994). Transforming growth factor /3: The good, the bad, 
and the ugly. J. Exp. Med. 180, 1587-1590. 
WOFFENDIN, C, YANG, Z.-Y., RANGA, U., XU, L., YANG, N.-S., 
SHEEHY, M.J., and NABEL, G.J. (1994). Nonviral and viral deliv-
ery of a human immunodeficiency virus protective gene into primary 
human T cells. Proc. Natl. Acad. Sci. U.S.A. 91, 11581-11585. 
YANG, Y., SU, Q., GREWAL, I.S., SCHILZ, R., FLAVELL, R.A., 
and WILSON, J.M. (1996). Transient subversion of CD40 ligand 
function diminishes immune responses to adenovirus vectors in 
mouse liver and lung tissues. J. Virol. 70, 6370-6377. 
YANKAUCKAS, M.A., M O R R O W , I.E., PARKER, S.E., ABAI, A., 
RHODES, G.H., DWARKI, V.J., and G R O M K O W S K I , S.H. (1993). 
Long-term anti-nucleoprotein cellular and humoral immunity is in-
duced by intramuscular injection of plasmid D N A containing NP 
gene. D N A Cell Biol. 12, 771-776. 
Address reprint requests to: 
Dr. D. Keith Bishop 
Transplant Immunology Research 
Section of General Surgery 
1150 W. Medical Center Drive 
A560 M S R B II, Box 0654 
Universiry of Michigan Medical Center 
Ann Arbor, M I 48109 
Received for publication March 11, 1998; accepted after revi-
sion July 17, 1998. 
